BioArctic AB (publ) (BRCTF), a Swedish research-based biopharma company on Tuesday announced that its partner Eisai has achieved the first sales milestone according to the licensing agreement as sales of Leqembi reached 200 million euros in Eisai fiscal year 2024 (April 2024 - March 2025). The event entitles BioArctic to a payment of 10 million euros.
Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic.
Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai.
BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.
For comments and feedback: editorial@rttnews.com